Bill Ackman’s fund raised its stake in Valeant Pharmaceuticals International Inc. to 9.9 percent in a series of transactions starting in October, underscoring the activist investor’s commitment to the embattled drugmaker.
Pershing Square Capital Management’s various funds have now amassed more than 34.1 million shares in the drugmaker, the activist hedge fund disclosed Monday in a regulatory filing. Ackman’s firm had previously disclosed a 5.7 percent stake in the drugmaker, as of Sept. 30.